Black Titan (NASDAQ:BTTC) versus VIQ Solutions (OTCMKTS:VQSLF) Financial Survey

Black Titan (NASDAQ:BTTC) and VIQ Solutions (OTCMKTS:VQSLF) are both small-cap services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Black Titan and VIQ Solutions, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
VIQ Solutions	0	0	0	0	0.00

Given VIQ Solutions’ higher possible upside, analysts clearly believe VIQ Solutions is more favorable than Black Titan.

Risk and Volatility

Black Titan has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, VIQ Solutions has a beta of -1.16, indicating that its share price is 216% less volatile than the S&P 500.

Valuation and Earnings

This table compares Black Titan and VIQ Solutions”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Titan	$180,000.00	55.65	-$4.71 million	($2.95)	-0.32
VIQ Solutions	$31.75 million	0.00	-$11.15 million	($0.50)	N/A

Black Titan has higher earnings, but lower revenue than VIQ Solutions. Black Titan is trading at a lower price-to-earnings ratio than VIQ Solutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Black Titan and VIQ Solutions’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	N/A	N/A
VIQ Solutions	-20.94%	-32.42%	-11.67%

Summary

Black Titan beats VIQ Solutions on 7 of the 10 factors compared between the two stocks.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

About VIQ Solutions

VIQ Solutions Inc. operates as a technology and service platform provider for digital evidence capture, retrieval, and content management in Australia, the United States, the United Kingdom, Canada, and internationally. It operates in two segments, Technology and Related Revenue, and Technology Services. The Technology segment develops, distributes, and licenses computer-based digital solutions based on its technology. The Technology Services segment provides recording and transcription services. The company offers CapturePro that securely speeds the capture, creation, and management of large volumes of information, as well as preserves and secures the spoken word and video image, and delivers data; MobileMic Pro for capturing and managing incident reports, recorded statements, case notes, and other vital information; NetScribe, a speech-to-text engine to consolidate, accelerate, and optimize transcription workflows; and aiAssist, a multi-tenant workflow and analysis platform to manage, convert, and analyze large volumes of audio and visual content. It also provides legal, criminal justice, insurance, government, corporate finance, and media transcription services. The company was incorporated in 2004 and is based in Mississauga, Canada.